June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Diagnostic aqueous humor proteome predicts metastatic potential in uveal melanoma
Author Affiliations & Notes
  • Chen-Ching Peng
    The Vision Center, Children's Hospital Los Angeles, Los Angeles, California, United States
  • Shreya Sirivolu
    USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States
  • Liya Xu
    The Vision Center, Children's Hospital Los Angeles, Los Angeles, California, United States
    USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States
  • Jesse L Berry
    The Vision Center, Children's Hospital Los Angeles, Los Angeles, California, United States
    USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Chen-Ching Peng None; Shreya Sirivolu None; Liya Xu None; Jesse Berry None
  • Footnotes
    Support  National Institute of Health (P30EY029220)
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1391. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chen-Ching Peng, Shreya Sirivolu, Liya Xu, Jesse L Berry; Diagnostic aqueous humor proteome predicts metastatic potential in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1391.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Gene expression profiling (GEP) is clinically validated to stratify metastasis risk by assigning uveal melanoma (UM) patients to two prognostic classes: class 1 (low metastatic risk) and class 2 (high metastatic risk). However, GEP requires intraocular tumor biopsy which are limited by small tumor size and tumor heterogeneity. Thus, liquid biopsy has emerged as a significantly less invasive alternative. Blood biopsy has largely been unsuccessful for clinical use in UM, however eye-specific aqueous humor (AH) liquid biopsy may be a better alternative. In this study, we seek to determine the AH proteome related to the advanced GEP class 2 using the diagnostic AH specimens.

Methods : Twenty UM treatment naive AH were collected before plaque brachytherapy. Patients were sub-grouped by GEP classes into GEP 1 (n=12) and GEP 2 (n=5). Three patients were classified as GEP unknown (GEP NA, n=3) due to the unavailability of tumor biopsy. Ten microliters of AH samples were analyzed by proximity extension assay-derived multiplexed platform. Protein expression levels of 1472 targets were analyzed, compared between GEP classes and correlated with clinical features. Significant differentially expressed proteins (DEPs) were subjected to Qiagen ingenuity pathway analysis for cellular pathway and upstream regulator analysis.

Results : GEP2 class was correlated with AJCC stages (P = 0.012), advanced clinical tumor stages (P = 0.007) and mutated BAP1 (P = 0.018). 45 DEPs were identified when comparing GEP classes. Among them, 31 are up-regulated DEPs [fold-change (FC) >2, P < 0.01] and 14 are down-regulated DEPs (FC < 0.5, P < 0.01) in GEP 2 compared to GEP1. The unsupervised clustering analysis showed that the 45 DEPs differentiate AH samples by GEP classes, and the 3 GEP NA samples were clustered with GEP1 class. Pathway analysis showed that 45 DEPs contribute to metastatic-related pathways. Two upstream regulators, IL1 receptor and SPRY2, were predicted to regulate 8 out of the 45 DEPs. IL1R2 (FC = 3.4, P = 0.021) and SPRY2 (FC = 0.6, P = 0.052) protein expression levels were found matched as prediction in our dataset.

Conclusions : 45 AH DEPs could differentiate GEP class 1 and 2 at the diagnostic stage and could be detected even when the tumor was too small to biopsy. IL1R and SPRY2 are potential upstream regulators for the 8/45 DEPs that contribute to metastasis-related pathways.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×